Role of Hydroxyapatite and Ellagic Acid in the Osteogenesis

Objective Ellagic acid (EA), a phenolic antioxidant, has benefits in bone health and wound healing. The combination of EA and hydroxyapatite (HA) (EA-HA) is expected to increase osteogenesis. The aim of this study was to analyze osteogenesis after appli-cation of EA-HA according to the number of ost...

Full description

Saved in:
Bibliographic Details
Main Authors: Agung Satria Wardhana, -, Intan Nirwana, -, Hendrik Setia Budi, -, Meircurius Dwi Condro Surboyo, -
Format: Article PeerReviewed
Language:English
English
English
English
Published: European Journal of Dentistry 2021
Subjects:
Online Access:https://repository.unair.ac.id/116938/1/8.Role%20of%20Hydroxyapatite%20and%20Ellagic%20Acid%20in%20the%20Osteogenesis.pdf
https://repository.unair.ac.id/116938/2/Plagiasi%20artikel%20no%208.pdf
https://repository.unair.ac.id/116938/4/Bukti%20Korespondensi%20Artikel%20no.%208.pdf
https://repository.unair.ac.id/116938/8/8..pdf
https://repository.unair.ac.id/116938/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906838/#:~:text=Objective%20Ellagic%20acid%20(EA)%2C,is%20expected%20to%20increase%20osteogenesis.
https://doi.org/ 10.1055/s-0040-1714039
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universitas Airlangga
Language: English
English
English
English
Description
Summary:Objective Ellagic acid (EA), a phenolic antioxidant, has benefits in bone health and wound healing. The combination of EA and hydroxyapatite (HA) (EA-HA) is expected to increase osteogenesis. The aim of this study was to analyze osteogenesis after appli-cation of EA-HA according to the number of osteoblasts and osteoclasts in the bone and the expression of the receptor activator of nuclear factor kappa- ligand (RANKL), osteoprotegerin (OPG), and osteocalcin (OCN) protein. Materials and Methods Thirty Wistar rats were assessed with bone defects created in the left femur. The defects were filled with EA-HA and then sutured. Control groups were filled with polyethylene glycol (PEG) or HA. Each group was sacrificed either 7 or 14 days after treatment. Results The defects filled with EA-HA exhibited the highest number of osteoblasts and the greatest expression of OPG and OCN at both day 7 and day 14 (p = 0.000). Conversely, treatment with EA-HA resulted in lower numbers of osteoclasts and reduced RANKL staining at both time points (p = 0.000). Conclusions EA-HA can increase osteogenesis in bone defects by increasing the number of osteoblasts and the expression of OPG and OCN.